186 related articles for article (PubMed ID: 31107158)
1. African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome.
Echevarria MI; Awasthi S; Cheng CH; Berglund AE; Rounbehler RJ; Gerke TA; Takhar M; Davicioni E; Klein EA; Freedland SJ; Ross AE; Schaeffer EM; Den RB; Cleveland JL; Park JY; Rayford W; Yamoah K
J Urol; 2019 Aug; 202(2):247-255. PubMed ID: 31107158
[TBL] [Abstract][Full Text] [Related]
2. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.
Cullen J; Rosner IL; Brand TC; Zhang N; Tsiatis AC; Moncur J; Ali A; Chen Y; Knezevic D; Maddala T; Lawrence HJ; Febbo PG; Srivastava S; Sesterhenn IA; McLeod DG
Eur Urol; 2015 Jul; 68(1):123-31. PubMed ID: 25465337
[TBL] [Abstract][Full Text] [Related]
3. Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.
Yamoah K; Johnson MH; Choeurng V; Faisal FA; Yousefi K; Haddad Z; Ross AE; Alshalafa M; Den R; Lal P; Feldman M; Dicker AP; Klein EA; Davicioni E; Rebbeck TR; Schaeffer EM
J Clin Oncol; 2015 Sep; 33(25):2789-96. PubMed ID: 26195723
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate Cancer.
Cullen J; Lynch JA; Klein EA; Van Den Eeden SK; Carroll PR; Mohler JL; Knezevic D; Farrington TA; Lu R
J Urol; 2021 Apr; 205(4):1047-1054. PubMed ID: 33493001
[TBL] [Abstract][Full Text] [Related]
5. Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study.
O'Malley PG; Nguyen DP; Al Hussein Al Awamlh B; Wu G; Thompson IM; Sanda M; Rubin M; Wei JT; Lee R; Christos P; Barbieri C; Scherr DS
J Urol; 2017 Jul; 198(1):42-49. PubMed ID: 28115190
[TBL] [Abstract][Full Text] [Related]
6. Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) tumor biomarker for identifying recurrent disease in African American patients.
Levin AM; Lindquist KJ; Avila A; Witte JS; Paris PL; Rybicki BA
Cancer Epidemiol Biomarkers Prev; 2014 Aug; 23(8):1677-82. PubMed ID: 24891551
[TBL] [Abstract][Full Text] [Related]
7. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
[TBL] [Abstract][Full Text] [Related]
8. Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.
Cullen J; Young D; Chen Y; Degon M; Farrell J; Sedarsky J; Baptiste W; Rosen P; Tolstikov V; Kiebish M; Kagan J; Srivastava S; Kuo HC; Moncur JT; Rosner IL; Narain N; Akmaev V; Petrovics G; Dobi A; McLeod DG; Srivastava S; Sesterhenn IA
Eur Urol Focus; 2018 Dec; 4(6):818-824. PubMed ID: 28753864
[TBL] [Abstract][Full Text] [Related]
9. Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location.
Faisal FA; Sundi D; Tosoian JJ; Choeurng V; Alshalalfa M; Ross AE; Klein E; Den R; Dicker A; Erho N; Davicioni E; Lotan TL; Schaeffer EM
Eur Urol; 2016 Jul; 70(1):14-17. PubMed ID: 26443432
[TBL] [Abstract][Full Text] [Related]
10. TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer.
Yamoah K; Lal P; Awasthi S; Naghavi AO; Rounbehler RJ; Gerke T; Berglund AE; Pow-Sang JM; Schaeffer EM; Dhillon J; Park JY; Rebbeck TR
Prostate; 2021 Feb; 81(2):109-117. PubMed ID: 33141952
[TBL] [Abstract][Full Text] [Related]
11. Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection.
Hughes L; Zhu F; Ross E; Gross L; Uzzo RG; Chen DY; Viterbo R; Rebbeck TR; Giri VN
Cancer Epidemiol Biomarkers Prev; 2012 Jan; 21(1):53-60. PubMed ID: 22144497
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
Canter DJ; Reid J; Latsis M; Variano M; Halat S; Rajamani S; Gurtner KE; Sangale Z; Brawer M; Stone S; Bardot S
Eur Urol; 2019 Mar; 75(3):515-522. PubMed ID: 30391079
[TBL] [Abstract][Full Text] [Related]
13. Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer.
Awasthi S; Berglund A; Abraham-Miranda J; Rounbehler RJ; Kensler K; Serna A; Vidal A; You S; Freeman MR; Davicioni E; Liu Y; Karnes RJ; Klein EA; Den RB; Trock BJ; Campbell JD; Einstein DJ; Gupta R; Balk S; Lal P; Park JY; Cleveland JL; Rebbeck TR; Freedland SJ; Yamoah K
Clin Cancer Res; 2021 Jan; 27(1):320-329. PubMed ID: 33037017
[TBL] [Abstract][Full Text] [Related]
14.
Faisal FA; Murali S; Kaur H; Vidotto T; Guedes LB; Salles DC; Kothari V; Tosoian JJ; Han S; Hovelson DH; Hu K; Spratt DE; Baras AS; Tomlins SA; Schaeffer EM; Lotan TL
Clin Cancer Res; 2020 Jun; 26(11):2595-2602. PubMed ID: 31969336
[TBL] [Abstract][Full Text] [Related]
15. Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison.
Ritch CR; Morrison BF; Hruby G; Coard KC; Mayhew R; Aiken W; Benson MC; McKiernan JM
BJU Int; 2013 Apr; 111(4 Pt B):E186-90. PubMed ID: 23107067
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.
Tosoian JJ; Almutairi F; Morais CL; Glavaris S; Hicks J; Sundi D; Humphreys E; Han M; De Marzo AM; Ross AE; Tomlins SA; Schaeffer EM; Trock BJ; Lotan TL
Eur Urol; 2017 May; 71(5):697-700. PubMed ID: 27477529
[TBL] [Abstract][Full Text] [Related]
17. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N
Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209
[TBL] [Abstract][Full Text] [Related]
18. Commercial Gene Expression Tests for Prostate Cancer Prognosis Provide Paradoxical Estimates of Race-Specific Risk.
Creed JH; Berglund AE; Rounbehler RJ; Awasthi S; Cleveland JL; Park JY; Yamoah K; Gerke TA
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):246-253. PubMed ID: 31757784
[TBL] [Abstract][Full Text] [Related]
19. Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS2:ETS fusion gene markers.
Chan SW; Nguyen PN; Violette P; Brimo F; Taguchi Y; Aprikian A; Chen JZ
Cancer Med; 2013 Feb; 2(1):63-75. PubMed ID: 24133629
[TBL] [Abstract][Full Text] [Related]
20. SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort.
Johnson MH; Ross AE; Alshalalfa M; Erho N; Yousefi K; Glavaris S; Fedor H; Han M; Faraj SF; Bezerra SM; Netto G; Partin AW; Trock BJ; Davicioni E; Schaeffer EM
J Urol; 2016 Nov; 196(5):1436-1444. PubMed ID: 27238617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
